Kura Oncology Reports $20.9 Million Revenue in Q2 2026, Driven by KOMZIFTI Sales

Kura Oncology, Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $20.9 million, a significant increase from $15.3 million in the same period last year. This growth was driven by the introduction of product revenue from KOMZIFTI, which generated $9.1 million in net sales during the quarter, following its FDA approval in November 2025. Collaboration revenue, however, saw a decline, dropping to $11.8 million from $15.3 million year-over-year, primarily due to reduced activity under the Kyowa License Agreement.

The company’s operating expenses for the second quarter totaled $93.9 million, up from $88.0 million in the prior year. This increase was largely attributed to higher selling, general, and administrative expenses, which rose to $31.8 million from $25.2 million, reflecting increased personnel costs and professional services. Research and development expenses remained relatively stable at $61.9 million, compared to $62.8 million in the previous year. Kura reported a net loss of $68.3 million for the quarter, slightly higher than the $66.1 million loss recorded in the same quarter of 2025.

Kura's balance sheet as of June 30, 2026, showed total assets of $587.8 million, a decrease from $738.4 million at the end of 2025. This decline was primarily due to a reduction in cash and cash equivalents, which fell to $70.2 million from $149.1 million. The company’s total liabilities also decreased to $539.4 million from $564.2 million, with long-term contract liabilities accounting for a significant portion of this figure. Stockholders' equity dropped to $48.4 million, down from $174.1 million at the end of the previous fiscal year, largely due to accumulated losses.

Strategically, Kura has made significant advancements in its product pipeline, particularly with KOMZIFTI, which is now included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines as a recommended treatment for adults with relapsed or refractory acute myeloid leukemia (AML). The company is also actively pursuing clinical trials for ziftomenib in various settings, including combination therapies for AML. Kura anticipates that its cash reserves, combined with expected payments under the Kyowa License Agreement, will be sufficient to fund operations into the fourth quarter of 2027.

Looking ahead, Kura Oncology expects to continue its focus on expanding the commercialization of KOMZIFTI while advancing its clinical development programs. The company acknowledges the need for additional funding to support ongoing research and development efforts, particularly as it seeks to enhance its product offerings and market presence in the oncology sector.